Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

Launched by NATIONAL CANCER CENTER, KOREA · May 7, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether a treatment called TSH suppression therapy is necessary for patients with a certain type of thyroid cancer called papillary thyroid carcinoma. In this study, participants will be randomly placed into two groups: one group will receive TSH suppression therapy to lower their thyroid-stimulating hormone levels, while the other group will not receive this treatment and will maintain higher levels of TSH. Researchers want to understand how these two approaches affect the management of thyroid cancer during a period called active surveillance, where doctors closely monitor patients without immediate treatment.

To be eligible for the trial, participants should have a thyroid nodule that is 1.0 cm or smaller and has been classified as suspicious or confirmed as cancer based on tests. They should not have any signs of spreading cancer or certain other serious health conditions. The trial is open to all genders and includes patients aged between 18 and 80 years. Those who join can expect regular follow-ups and monitoring to assess their condition over time, contributing valuable information to help improve care for thyroid cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.
• • Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).
• • Non-pregnant women of childbearing potential (confirmed by medical history taking)
• Exclusion Criteria:
• • Hyperthyroidism
• * If the investigator determines that you are not suitable for clinical research participation considering the following comorbidities:
• • Myocardial infarction or cerebrovascular accident within the last three months.
• • Diseases with limited life expectancy or potentially impairing the patient's ability to comply with at least five years of treatment or follow-up.